Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
Status:
Completed
Trial end date:
2017-07-05
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once
daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause
in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.